22 September 2022 The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies read more
14 September 2022 Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering read more
12 September 2022 Scorpion Therapeutics, Volastra Therapeutics and ReCode Therapeutics Selected in Fierce Biotech’s 2022 Fierce 15 read more
29 June 2022 ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M read more
15 June 2022 Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients read more
